| | Authors and year | Study design | Enrolled population | Samples | Gestational age at sampling (weeks) | Techniques | ↑ miRNAs | ↓ miRNAs |
| | Wu et al., 2012 [23] | Retrospective | 10 cases + 10 controls | Maternal serum | 37–40 | miRNA microarray + qRT-PCR | miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p (cases) | | | Choi et al., 2013 [8] | Retrospective | 21 cases + 20 controls | Placental tissue | 35–40 | miRNA microarray + qRT-PCR | miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p (cases) | miR-21 and miR-223 (cases) | | Ura et al., 2014 [24] | Retrospective | 24 cases + 24 controls | Maternal serum | 12–14 | TLDA + qRT-PCR | miR-1233, miR-520, miR-210 (cases) | miR-144 (cases) | | Li et al., 2013 [9] | Retrospective | First step:4 mild PE + 4 severe PE + 4 controls | Maternal serum | 32–38 | SOLiD sequencing | miR-519d, miR-517b, miR-517c, miR-26b, miR-221, miR-521, miR-378, miR-519a, miR-520h, miR-125b, miR-29a, miR-125a-5p, miR-114, miR-30a, miR-518c, miR-27a, miR-519e, miR-130a, miR-515-3p, miR-299a-5p, miR-518b, miR-23a, miR-23b, miR-34a, miR-424, miR-525-3p, miR-199a-5p, miR-29b, miR-99a, miR-21, miR-145, miR-512-5p, and miR-30b (mild and severe PE) | miR-15b, miR-223, miR-320c, miR-185, miR-107, miR-451, and let-7f (mild and severe PE) | | miR-19a, miR-10a, miR-144, miR-151b, miR-144, miR-182, and miR-19b (severe PE) | miR-19a, miR-144, miR-19b, and miR-25 (mild PE) | Validation step:
16 mild PE + 22 severe PE + 32 controls | 28–38 | qRT-PCR | miR-141, miR-29a, (mild PE) | miR-144 (mild PE) | | miR-141, miR-221, and miR-29a (severe PE) | | Munaut et al., 2016 [10] | Retrospective | 23 cases + 44 controls | Maternal serum | 31-32 | qRT-PCR | miR-210-3p, miR-210-5p, miR-1233-3p, and miR-574-5p (PE women) | — | | Sandrim et al., 2016 [25] | Retrospective | Screening:
5 cases + 4 controls | Maternal plasma | 35 | PCR array + qRT-PCR | miR-885-5p (PE women) | miR-376c-3p, miR-19a-3p, and miR-19b-3p (PE women) | Case control study:
19 cases + 14 controls | 35 | miR-885-5p (PE women) | — | Replication study:
8 cases + 8 controls | 35 | miR-885-5p (PE women) | — | | Hromadnikova et al., 2017 [26] | Retrospective | 21 PE + 58 controls | Maternal plasma | 10-11 | qRT-PCR | miR-517-5p, miR-518b, and miR-520h (PE women) | — |
|
|
